Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; however, recently,...

ver descrição completa

Detalhes bibliográficos
Autores: Rodríguez-Espinosa, Diana, Broseta, José Jesús|||0000-0002-4559-9083, Bastida, Carla|||0000-0003-0845-8107, Álvarez Mora, María Isabel|||0000-0003-3788-8915, Nicolau, Carlos|||0000-0002-1381-6442, Alvarez, Cristina, Agraz Pamplona, Irene|||0000-0002-4223-6834, Sánchez-Baya, Maya|||0000-0003-1689-9383, Furlano, Monica|||0000-0003-1025-3901, Ruiz, César, Quintana, Luis F.|||0000-0001-7582-8476, Piñeiro, Gastón Julio|||0000-0003-3806-4731, Poch, Esteban|||0000-0002-6492-024X, Torra Balcells, Roser|||0000-0001-8714-2332, Blasco Pelicano, Miquel|||0000-0003-0789-7992
Tipo de documento: artigo
Data de publicação:2022
País:España
Recursos:Universitat Autònoma de Barcelona
Repositório:Dipòsit Digital de Documents de la UAB
Idioma:inglês
OAI Identifier:oai:ddd.uab.cat:281651
Acesso em linha:https://ddd.uab.cat/record/281651
https://dx.doi.org/urn:doi:10.1159/000526368
Access Level:Acceso aberto
Palavra-chave:ADPKD
Creatine-kinase
Side effect
Tolvaptan
id ES_cfe628f6c1bfd6afdfedef03bb514325
oai_identifier_str oai:ddd.uab.cat:281651
network_acronym_str ES
network_name_str España
repository_id_str
spelling Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan TreatmentRodríguez-Espinosa, DianaBroseta, José Jesús|||0000-0002-4559-9083Bastida, Carla|||0000-0003-0845-8107Álvarez Mora, María Isabel|||0000-0003-3788-8915Nicolau, Carlos|||0000-0002-1381-6442Alvarez, CristinaAgraz Pamplona, Irene|||0000-0002-4223-6834Sánchez-Baya, Maya|||0000-0003-1689-9383Furlano, Monica|||0000-0003-1025-3901Ruiz, CésarQuintana, Luis F.|||0000-0001-7582-8476Piñeiro, Gastón Julio|||0000-0003-3806-4731Poch, Esteban|||0000-0002-6492-024XTorra Balcells, Roser|||0000-0001-8714-2332Blasco Pelicano, Miquel|||0000-0003-0789-7992ADPKDCreatine-kinaseSide effectTolvaptanAutosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; however, recently, there have been two reports of creatine kinase (CK) elevation in ADPKD patients on tolvaptan treatment. We set out to monitor and determine the actual incidence of CK elevation and evaluate its potential association with other clinical factors. This is an observational retrospective multicenter study performed in rapidly progressive ADPKD patients on tolvaptan treatment from Barcelona, Spain. Laboratory tests, demographics, treatment dose, and reported symptoms were collected from October 2018 to March 2021. Ninety-five patients initiated tolvaptan treatment during follow-up. The medication had to be discontinued in 31 (32.6%) patients, primarily due to aquaretic effects (12.6%), elevated liver enzymes (8.4%), and symptomatic or persistently elevated CK levels (3.2%). Moreover, a total of 27 (28.4%) patients had elevated CK levels, with most of them being either transient (12.6%), mild and asymptomatic (4.2%), or resolved after dose reduction (3.2%) or temporary discontinuation (2.1%). We pre sent the largest cohort that has monitored CK levels in a real-life setting, finding them elevated in 28.4% of patients. More research and monitoring will help us understand the clinical implications and the pathophysiological mechanism of CK elevation in this population.Universitat Autònoma de Barcelona 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/281651https://dx.doi.org/urn:doi:10.1159/000526368reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2816512026-06-06T12:50:31Z
dc.title.none.fl_str_mv Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
title Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
spellingShingle Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
Rodríguez-Espinosa, Diana
ADPKD
Creatine-kinase
Side effect
Tolvaptan
title_short Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
title_full Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
title_fullStr Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
title_full_unstemmed Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
title_sort Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
dc.creator.none.fl_str_mv Rodríguez-Espinosa, Diana
Broseta, José Jesús|||0000-0002-4559-9083
Bastida, Carla|||0000-0003-0845-8107
Álvarez Mora, María Isabel|||0000-0003-3788-8915
Nicolau, Carlos|||0000-0002-1381-6442
Alvarez, Cristina
Agraz Pamplona, Irene|||0000-0002-4223-6834
Sánchez-Baya, Maya|||0000-0003-1689-9383
Furlano, Monica|||0000-0003-1025-3901
Ruiz, César
Quintana, Luis F.|||0000-0001-7582-8476
Piñeiro, Gastón Julio|||0000-0003-3806-4731
Poch, Esteban|||0000-0002-6492-024X
Torra Balcells, Roser|||0000-0001-8714-2332
Blasco Pelicano, Miquel|||0000-0003-0789-7992
author Rodríguez-Espinosa, Diana
author_facet Rodríguez-Espinosa, Diana
Broseta, José Jesús|||0000-0002-4559-9083
Bastida, Carla|||0000-0003-0845-8107
Álvarez Mora, María Isabel|||0000-0003-3788-8915
Nicolau, Carlos|||0000-0002-1381-6442
Alvarez, Cristina
Agraz Pamplona, Irene|||0000-0002-4223-6834
Sánchez-Baya, Maya|||0000-0003-1689-9383
Furlano, Monica|||0000-0003-1025-3901
Ruiz, César
Quintana, Luis F.|||0000-0001-7582-8476
Piñeiro, Gastón Julio|||0000-0003-3806-4731
Poch, Esteban|||0000-0002-6492-024X
Torra Balcells, Roser|||0000-0001-8714-2332
Blasco Pelicano, Miquel|||0000-0003-0789-7992
author_role author
author2 Broseta, José Jesús|||0000-0002-4559-9083
Bastida, Carla|||0000-0003-0845-8107
Álvarez Mora, María Isabel|||0000-0003-3788-8915
Nicolau, Carlos|||0000-0002-1381-6442
Alvarez, Cristina
Agraz Pamplona, Irene|||0000-0002-4223-6834
Sánchez-Baya, Maya|||0000-0003-1689-9383
Furlano, Monica|||0000-0003-1025-3901
Ruiz, César
Quintana, Luis F.|||0000-0001-7582-8476
Piñeiro, Gastón Julio|||0000-0003-3806-4731
Poch, Esteban|||0000-0002-6492-024X
Torra Balcells, Roser|||0000-0001-8714-2332
Blasco Pelicano, Miquel|||0000-0003-0789-7992
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv ADPKD
Creatine-kinase
Side effect
Tolvaptan
topic ADPKD
Creatine-kinase
Side effect
Tolvaptan
description Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; however, recently, there have been two reports of creatine kinase (CK) elevation in ADPKD patients on tolvaptan treatment. We set out to monitor and determine the actual incidence of CK elevation and evaluate its potential association with other clinical factors. This is an observational retrospective multicenter study performed in rapidly progressive ADPKD patients on tolvaptan treatment from Barcelona, Spain. Laboratory tests, demographics, treatment dose, and reported symptoms were collected from October 2018 to March 2021. Ninety-five patients initiated tolvaptan treatment during follow-up. The medication had to be discontinued in 31 (32.6%) patients, primarily due to aquaretic effects (12.6%), elevated liver enzymes (8.4%), and symptomatic or persistently elevated CK levels (3.2%). Moreover, a total of 27 (28.4%) patients had elevated CK levels, with most of them being either transient (12.6%), mild and asymptomatic (4.2%), or resolved after dose reduction (3.2%) or temporary discontinuation (2.1%). We pre sent the largest cohort that has monitored CK levels in a real-life setting, finding them elevated in 28.4% of patients. More research and monitoring will help us understand the clinical implications and the pathophysiological mechanism of CK elevation in this population.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/281651
https://dx.doi.org/urn:doi:10.1159/000526368
url https://ddd.uab.cat/record/281651
https://dx.doi.org/urn:doi:10.1159/000526368
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420124936601600
score 15,301603

Registros relacionados